Spending on Rare Disease Treatments Such as LEMS Comparatively Low
In the U.S., treatments for rare diseases such as Lambert-Eaton myasthenic syndrome (LEMS) account for only 11% of total medical invoice spending in the country, according to a recent report. The report, “Orphan Drugs in the United States: Rare Disease Innovation and Cost Trends Through 2019,” is…